Monday 21 October 2019

Bronchoscopes Market Segmentation Detailed Study with Forecast Up To 2019

Market Scenario
Bronchoscopy has become an essential part of modern medicine. The examination by bronchoscopy has become the most common method to diagnose any kind of abnormality in the normal function of the respiratory system. Bronchoscopes are the instruments used for visualizing the insides of the patient’s airways. Bronchoscopes are usually inserted through nose or mouth, and occasionally through the trachea. Owing to the recent advances in medicine, a number of bronchoscopes have been introduced. Flexible bronchoscopes have been introduced to diagnose the diseases in trachea and the bronchi. Due to their different advantages, they are widely accepted throughout various countries and regions. The global bronchoscope market is majorly driven by increasing prevalence of respiratory tract diseases for instant, lung cancer and COPD, increasing number of bronchoscopies procedures, and increasing preference for minimally invasive procedures. According to the WHO (World Health Organization), in 2015, 64 million people have chronic obstructive pulmonary disease (COPD), whereas, over 3 million people died of COPD. Additionally 1.8 million people across the globe were suffering from lung cancer. Increasing number of healthcare organization and patient inflow have boosted the number of bronchoscopy procedures. Moreover, increasing geriatric population, increasing healthcare expenditure, and changing environmental condition have fuelled the growth of the market over the review period. However, high cost of the devices and risk of infection may slow the growth of the market.
The market for bronchoscopes is growing at a healthy pace. The market is expected to grow at the CAGR of 7.4% during the forecast period and is estimated to reach USD 2,244.4 million by 2023.

Segmentation                                                                                                                                      
The global bronchoscopes market is segmented on the basis of types, application, and end users.
On the basis of types, the market is segmented into rigid bronchoscopes, and flexible bronchoscopes. Flexible bronchoscopes are further sub-segmented into fiber optic bronchoscopes, and video bronchoscopes.
On the basis of application, the market is segmented into diagnosis, and surgical procedure. Diagnosis is further segmented into examination, patient’s airways, bleeding lungs, possibility of lung cancer, chronic cough, and obtain tissue specimen for biopsy. Surgical procedure is further segmented into removal of a foreign object in the airway, laser resection of tumors, lung abscess, stent insertion, percutaneous tracheostomy, and tracheal intubation.
On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers and others. 
Key Players for Global Bronchoscopes Market
Some of the major players in this market are: Ambu Inc. (US), Boston Scientific Corporation (US), Cogentix Medical (US), Fujifilm Holdings Corporation (Japan), Olympus Corporation (Japan), Pentax Medicals (Japan), and KARL STORZ GmbH & Co. KG (Germany), Schindler Endoskopie Technologie Gmbh (Germany), Schölly Fiberoptic Gmbh (Germany), Vimex Sp. (Poland), Hangzhou EndoTop Medi-Tech Co., Ltd.(China), Guangzhou MeCan Medical Limited (China), and LocaMed (UK).
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Tuesday 15 October 2019

Osteoporosis Drugs Market 2019–By Identifying the Key Market Segments and Key players holding market share

The Global Osteoporosis Market is currently eyeing for a staggering USD 14,300 million valuation during the forecast period (2013-2022), claims Market Research Future (MRFR) in a detailed study. Booming urbanization and technological advancements may have a lot to do with the progressing world, but they have some adverse effects too. Osteoporosis is one such side-effect of the fast-evolving lifestyle and the inflating osteoporosis drugs market is a direct result of that. The market is about to witness a moderate CAGR of 4.7% during the forecast period.
The Osteoporosis Drugs market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.
The market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.
Osteoporosis is weakening of bones due to lower bone mass resulting in and micro-architectural deterioration of bone tissue and subsequent higher risk of a broken fracture. It generally occurs at an advanced age and women are more susceptible to it than males by about three to four folds. WHO estimates that around 1.66 million hip fractures occur each year worldwide due to osteoporosis. According to national osteoporosis foundation about 54 million Americans suffer from osteoporosis.
The disease also has a genetic bias in that it Caucasians are more affected than Asians. The disease prevalence is lowest in African population.
Key Players:
  • Eli Lilly and Company
  • Merck & Co.
  • Novartis International AG
  • Amgen Inc.
  • Hoffmann La Roche Ltd.
  • Pfizer Inc.
  • Novo Nordisk
  • Teva Pharmaceutical Industries Ltd
Segmentation:
Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female.
Regional Analysis
Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.
Intended Audience:
  • Osteoporosis Drugs Manufacturers
  • Osteoporosis Drugs Suppliers
  • Private Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Government Research Laboratories
  • Contract Manufacturing Organizations
Browse Premium Research Report with Tables of Contents @ https://www.marketresearchfuture.com/reports/osteoporosis-drugs-market-2479
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Monday 14 October 2019

Age-Related Macular Degeneration Market to Observe Strong Development by 2019

Market scenario:
This MRFR study offers a vivid view of the global age-related macular degeneration AMD market. The study includes an in-depth analysis of macro and micro-economic factors likely to influence the market during the forecast period. It further summarizes the key market opportunities and trends.
The Global Age-Related Macular Degeneration Market is expected to register a CAGR of 7.80% to reach USD 11,186.8 Million by 2023. Age-related macular degeneration (AMD) is a chronic irreversible medical condition that results in central vision loss because of damage to the central area of the retina (macula). This condition is majorly categorized as dry age-related macular degeneration and wet age-related macular degeneration.
Growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off-patent are expected to enhance market growth. However, factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Key Players
The prominent players in the global age-related macular degeneration market are Novartis AG, Pfizer Inc, F. Hoffmann-La Roche AG, Acucela Inc., Ophthotech Corporation, GlaxoSmithKline PLC, Bayer AG, Rxi Pharmaceuticals, Inc., Regeneron Pharmaceutical Inc., Alimera Sciences Inc., Santen Pharmaceuticals Co., ALLERGAN, and Bausch & Lomb Incorporate.
Market Dynamics
The global age-related macular degeneration market has been primarily driven by growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off patent. For instance, according to the 2017 statistics suggested by the United Nations, it was estimated that 962 million people aged 60 or above comprise 13% of the global population. Factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Segmentation
The global age-related macular degeneration market has been segmented into type, stages, age group, treatment, and route of administration. Based on type, the market has been classified as wet age-related macular degeneration (wet AMD) and dry age-related macular degeneration (dry AMD). Dry age-related macular degeneration (dry AMD) held a market share of 2,092.6 USD million in 2017. Based on stages the market has been divided into intermediate-stage age-related macular degeneration, early-stage age-related macular degeneration, late-stage age-related macular degeneration. On the basis of age group, the market has been bifurcated into above 75 years, above 60 years, and 40 years. Based on treatment, the market has been divided into treatment and Diagnosis. Based on the route of administration, the market has been classified as an intravitreal route of administration and intravenous route of administration. Based on the end user, the market has been segmented into hospital & clinics, diagnostic centers, and academic research institutes.
Regional Analysis
The global age-related macular degeneration market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas dominate the global age-related macular degeneration market is owing to the rising ophthalmological disorders and increasing aging population. Nearly 7.3 million people are at significant risk of vision loss due to AMD.
Europe holds the second largest market share due to increasing older population and rising patient population. Additionally, improving government initiatives and increasing healthcare frame along with growing demand for technologically innovative treatment is driving the growth of age-related macular degeneration market in Europe
Asia-Pacific is estimated to be the fastest-growing region in the global age-related macular degeneration as it is developing at a very rapid pace and has shown the emergence of many players. Moreover, rising prevalence of eye disorders, increasing healthcare spending, and multinational companies moving towards the developing nations and setting operational set-ups are likely to drive the growth of the market. Japan held a market share of 23.2% in 2017.
The Middle East & Africa are expected to witness restricted growth due to limited access and healthcare affordability among the population. In the Middle East, the growth of the market is driven by increasing healthcare infrastructure and healthcare expenditure.
Browse Complete 220 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Liquid Biopsy Market to Observe Strong Development by 2019

Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.
Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart.
Segmentation:
Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centres and others.
Major Players
  • Guardant Health, Inc.,
  • Trovagene, Inc.,
  • RainDance Technologies, Inc.,
  • Agena Bioscience Inc. Inc.,
  • Admera Health,
  • Biocept, Inc.,
  • Circulogene Theranostics,
  • Inivata Ltd.,
  • SAGA Diagnostics AB,
  • Exosome Diagnostics and others.

Drivers
The market drivers for the liquid biopsy market are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Also the technique is not applicable to all types of cancer as some cancers such as brain cancer and prostate cancer may lie dormant for many years, and thus are either undetectable or detected very late which robs liquid biopsy of its advantages. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.

Regional Analysis:
Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster.
Key findings
  • Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.
  • On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.
  • The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period

Browse Complete 171 Pages Premium Research Report Enabled with 248 Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Chemotherapy Market to Observe Strong Development by 2019

Chemotherapy Market 2019 offered by Market Research Future (MRFR), The Global Chemotherapy Market is Expected to register a CAGR of 11.50% to reach USD 56,491.59 Million by 2024. Global Chemotherapy Industry by Drug Class, Indication, Route of Drug Administration and End-User and Forecast till 2024
The increasing prevalence of cancer, increasing expenditure on oncology medicine and research, and reimbursements and growing health insurance are driving the growth of the global chemotherapy market. 
Chemotherapy is one of the types of cancer treatment, which includes the use of one or more chemotherapeutic agents such as anti-cancer drugs. The treatment prevents the division of cancer cells and the growth of cancer cells by killing dividing cells. It is used for the treatment of various types of cancers such as lung cancer, breast cancer, leukemia, myeloma, sarcoma, lymphoma, ovarian cancer, and others.
Market Dynamics
The global chemotherapy market has been largely benefited by the increasing demand for chemotherapy products across the world. Increasing prevalence of cancer; increasing expenditure on oncology medicine and research, and reimbursements and growing health insurance are expected to spur market growth during the forecast period. Moreover, the patent expiry of leading drugs, government initiatives, and increasing public awareness about various diseases and treatment options are further expected to boost the growth of the global chemotherapy market during the review period.
Segmentation
The Global Chemotherapy has been segmented into major four segments, including drug class, route of administration, indication, and end user.
On the basis of drug class, the market is segmented into alkylating agents, mitotic inhibitors, antimetabolites, topoisomerase inhibitors, and antitumor antibiotic. The alkylating agents segment is expected to lead the market and register a substantial CAGR to reach USD 20,360.32 million by the end of 2024 and projected to exhibit the highest CAGR of 11.83% from 2019 to 2024.
Furthermore, based on indication, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, lymphoma, leukemia, ovarian cancer, and others.  Lung cancer accounted for the largest market share and expected to grow with the CAGR of 11.88% during the forecast period.
On the basis of route of administration, the market is segmented into intravenous, oral, subcutaneous, intra-muscular, intravesicular, topical, intraperitoneal, and intraventricular/intrathecal. Intravenous accounted for the largest market share. However, the oral segment is expected to grow at the fastest CAGR of 11.95% during the forecast period.
On the basis of end user, the market is segmented into, specialty centers, hospitals & clinics, others
Key Players
The prominent players in the global chemotherapy market are Johnson & Johnson Services Inc (US), GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (US), Merck & Co. Inc. (US), Sanofi S.A. (France), Celgene Corporation (US) and Bristol-Myers Squibb Company (US).
Regional Analysis
Geographically the chemotherapy market is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Americas accounted for the largest market share of 41.04% in 2018, and the regional market is projected to register a CAGR of 10.88%during the forecast period. North America is one of the leading markets in the region, accounting for the largest market share during the review period.  
The European market is estimated to exceed USD 18,292.73 Million by 2024. The accessibility to advanced treatment facilities, rising government initiatives to promote research to find a cure to the increasing number of cancer cases, and growing healthcare expenditure are driving the growth of the chemotherapy market in the region. Germany is the major contributor to the growth of the regional market, followed by France.
The market in Asia-Pacific is expected to be the fastest growing market. This high growth is mainly attributed to the increasing R&D funding by developing countries such as China and India for the development of the healthcare sector. Various other factors that influence the growth of the market include growing incidence of cancer, aging population, increasing demand for advanced therapies, patent expiry of leading drugs, government initiatives, and increasing public awareness about various diseases and treatment options.
The Middle East & Africa commands the least market share of the chemotherapy market, owing to fewer developments and extremely low income but, is expected to grow with better chemotherapy treatments. As the population is rapidly aging, cancer treatment is expected to increase in this region
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/chemotherapy-market-5791
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Precision Medicine Market Expected to Boost during 2019 To 2023

Global Precision Medicine Market To Ascend Pervasively By 2023, Registering more than US$ 126.14 Million Revenue; Asserts MRFR
Precision Medicine Market Research Report Published by Market Research Future with their exclusive analysis segmented by Ecosystem Players , Sub-Markets, Therapeutics and Regions and Forecast till 2025
The major market driving factor for precision medicine are patient’s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.
Precision medicine refers to medicines developed as per an individual’s genetic profile that helps as a guide for the prevention, diagnosis and treatment of diseases. The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2025. Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2025.
The market constraints include potential threat to personal data, high diagnostic cost as a barrier, potential risk of hardware or software failure, stringent regulations and standards, lack of awareness about the possible applications of precision medicine, reimbursement policies and regulatory framework, limited knowledge about the application of test and techniques, lack of research and evidences creating hindrances in its application.
Key Players for Global Precision Medicine Market:
Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biomérieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine
Key Findings:
  • The global precision medicine market is expected to reach USD 88.64 billion by 2025.
  • By ecosystem diagnostic tool companies holds the largest market share of precision medicine market and is expected to reach USD 27.56 billion by 2025.
  • By sub-market, company diagnostics holds the largest market share of precision medicine market and is expected to reach USD 21.32 billion by 2025.
Segmentation
The global precision medicine market has been segmented into ecosystem players, sub-markets, and therapeutics.
Based on ecosystem players, the global market has been segmented into pharmaceuticals and biotechnology companies, diagnostic companies, healthcare IT specialists/big data companies, and clinical laboratories. The diagnostic tool companies segment accounted for a market value of USD 16.27 million in 2017.
Based on sub-markets, the global market has been segmented into companion diagnostics, biomarker-based test, targeted therapeutics, pharmacogenomics (PGX), molecular diagnostics, and others.
Based on therapeutics, the global market has been segmented cancer/oncology, cardiovascular disease (CVD), central nervous system, infectious diseases, and others.
Regional Analysis
Globally North America is the largest market for global precision medicine. Europe is the second-largest market for global precision medicine. The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.
Browse Complete 313 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/precision-medicine-market-925
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Telehealth Market Expected to Grow at High Cagr during Forecast Period 2019 – 2023

Growing demand from the Healthcare sector and sustained sales among dynamic economies across the globe will remain the key factors driving the growth of the Global Telehealth Market during the next five years. According to a latest research report published by Market Research Future, titled "Telehealth Market Research Report- Global Forecast till 2023," the global market for Teleahealth is presumed to witness very high growth terms of revenue.
Market Scenario:
An expert on premium research reports, Market Research provides an in-depth analysis of regional data with Growth Potential, Opportunities, Drivers, Industry-Specific Challenges
Telehealth or telemedicine is a mode of delivering health care services to patients by using communication technologies to facilitate the diagnosis, treatment, consultation, education care management, and others. Telehealth acts as a bridge to improve the relationship between patient and healthcare providers as well as for improving patient satisfaction & behavioural changes by providing healthcare guidance and treatment. It provides self-management and caregiver’s support to the patients.  Telehealth is used to monitor the chronic diseases as well as to monitor disease from home.
There are tremendous benefits offered by the telehealth solutions. Some of these include improved access to the patients; telehealth can allow us to provide healthcare services to the patients situated in distant locations. It also allows physicians & doctors to expand their reach and services beyond their clinics. Telehealth services have also proved to be cost effective with increased efficiency through better management of chronic diseases. And also it reduces the travel time for the patients which further reduced costs for the patients. All these advantages have attracted healthcare services providers to adopt telehealth technologies and the demand for the same has been on the rise ever since.
The global telehealth market is driven by increasing prevalence of chronic diseases, rising geriatric population, and continuous development in the healthcare technology; as per statistics, more than 50% of the total globe population have some or other chronic disease. Moreover, rapid development in the technology, increasing healthcare expenditure, and increasing need for the home based devices have fuelled the market growth. However, lack of awareness and unavailability or less availability of the required infrastructure in many parts of the world including the underdeveloped Asian and African regions may slow the growth of the market.
The global teleheatlh market is expected to grow at a healthy CAGR of 29.8% during the forecasted period.
Key players
Some of the major players in the global telehealth market are Koninklijke Philips N.V. (the Netherlands), Medtronic (Ireland), General Electric Company (UK), McKesson Corporation (US), Care Innovations, LLC. (US), Cerner Corporation (US), GlobalMedia Group, LLC (US), Siemens Healthcare Private Limited (US), AMD Global Telemedicine, Inc. (US), InTouch Technologies, Inc. (US). 
Segmentation
The global telehealth market is segmented on the basis of components, types, and end users.
On the basis of component, the market is segmented into hardware, software, and others. Hardware is further segmented into monitors, medical devices, and others. Monitors are further segmented into blood glucose monitors, blood pressure monitors, ECG monitors, and others.
On the basis of types, the market is segmented into web based, on-premises, and cloud based. On the basis of end users the market is segmented into hospitals & clinics, pharmaceutical companies, and others. 
Regional Analysis
On the regional basis the global telehealth market is dominated by America owing to the presence of huge geriatric population and large number of people suffering from diabetes and other chronic respiratory diseases. Among all the regions in the world, the U.S. has been the first choice for the deployment of telehealth solutions due to established healthcare systems and technology advancement. It has gained a significant position in the global market with the increase in large numbers of telehealth services which target at wellness and fitness. Thus, these telehealth solutions help in cost reduction, saves time by reducing visits to physicians, and provides better healthcare systems. In Addition to this, well developed healthcare sector and high healthcare spending has contributed in the growth of the market. Europe accounts for the second largest market for the global telehealth market which is followed by Asia Pacific. The Germany is dominating the connected healthcare deployments in Europe, with different kinds of solutions being offered and services being delivered through varied means, from simple messages to much more complex apps. Asia pacific has the fastest growth market due to the presence of rapidly developing economies like China and India. However, the Middle East and Africa has the least share in the market.
Browse Complete 80 Pages Premium Research Report Enabled with 64 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/telehealth-market-900
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com